Literature DB >> 24896776

Electron microscopic features of nasal mucosa treated with topical and circumostial injection of mitomycin C: implications in dacryocystorhinostomy.

Mohammad Javed Ali1, Farhana Baig, Mekala Lakshman, Milind N Naik.   

Abstract

PURPOSE: To evaluate the ultrastructural effects of topical and circumostial injection of mitomycin C (COS-MMC) on nasal mucosa and compare them with the controls. The study also aimed at classifying the subcellular effects in detail.
METHODS: The nasal mucosa of 6 patients were subjected to 0.02% of mitomycin C for 3 minutes (3 patients) and 0.02% COS-MMC (3 patients) as per standard protocol, during endoscopic dacryocystorhinostomy. Normal nasal mucosa from untreated areas (2 each from topical and COS-MMC groups) were taken as controls after harvesting the treated areas. Full thickness tissues (5 mm × 5 mm) were collected for transmission electron microscopy, and ultrastructural effects were evaluated.
RESULTS: Both topical and COS-MMC showed significant and distinct ultrastructural changes involving the epithelial, glandular, vascular, and fibrocollagenous tissues compared with the controls. There were profound changes within fibroblasts with intracellular edema, pleomorphic and vesicular mitochondria, dilated smooth and rough endoplasmic reticulum, and chromatin condensation. In addition, COS-MMC samples showed subepithelial hypocellularity with limited disorganization of structure. The changes in both the MMC groups were restricted to treated areas only.
CONCLUSIONS: Both topical and COS-MMC show profound changes in nasal mucosa with more marked changes in COS-MMC group. These changes being limited in nature may help in enhancing the success of dacryocystorhinostomy by preventing cicatricial changes of the ostium, especially in high-risk cases such as revision and post-traumatic dacryocystorhinostomy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24896776     DOI: 10.1097/IOP.0000000000000205

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  8 in total

1.  Safety and efficacy of adjunctive intranasal mitomycin C and triamcinolone in endonasal endoscopic dacryocystorhinostomy.

Authors:  Emmy Y Li; Andy C Cheng; Alex C Wong; Amy M Sze; Hunter K Yuen
Journal:  Int Ophthalmol       Date:  2015-05-26       Impact factor: 2.031

2.  Efficacy of adjunctive mitomycin C in transcanalicular diode laser dacryocystorhinostomy.

Authors:  Mustafa Ozsutcu; Ozlem Balci; Cafer Tanriverdi; Goktug Demirci
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-23       Impact factor: 2.503

3.  Endoscopic ultrasonic dacryocystorhinostomy: clinical profile and outcomes.

Authors:  Mohammad Javed Ali; Manpreet Singh; Naja Chisty; Saurabh Kamal; Milind N Naik
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-03       Impact factor: 2.503

4.  Antimetabolites as an adjunct to dacryocystorhinostomy for nasolacrimal duct obstruction.

Authors:  Paul O Phelps; Samuel A Abariga; Benjamin J Cowling; Dinesh Selva; Marcus M Marcet
Journal:  Cochrane Database Syst Rev       Date:  2020-04-07

5.  Electron microscopy in the understanding of lacrimal drainage system.

Authors:  Mohammad Javed Ali
Journal:  Saudi J Ophthalmol       Date:  2015 Jul-Sep

Review 6.  Mitomycin-C in dacryocystorhinostomy: From experimentation to implementation and the road ahead: A review.

Authors:  Akshay Gopinathan Nair; Mohammad Javed Ali
Journal:  Indian J Ophthalmol       Date:  2015-04       Impact factor: 1.848

7.  Efficacy of Intraoperative Mitomycin-C in Vasovasostomy Procedure: A Randomized Clinical Trial.

Authors:  Farzad Allameh; Jalil Hosseini; Hamidreza Qashqai; Hamzeh Mazaherylaghab
Journal:  Int J Fertil Steril       Date:  2019-07-14

8.  Causes of unsatisfactory results of the use of mitomycin-C in endoscopic endonasal dacryocystorhinostomy.

Authors:  E L Atkova; A A Fedorov; A O Root; S D Iartsev; N N Krakhovetsky; V D Yartsev
Journal:  Saudi J Ophthalmol       Date:  2017-05-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.